

# CYLCHLYTHYR IECHYD CYMRU



Llywodraeth Cymru  
Welsh Government

**Dyddiad cyhoeddi:** 27 Awst 2021

**STATWS: CYDYMFFURFIO / GWEITHREDU / GWYBODAETH**

**CATEGORI: IECHYD Y CYHOEDD**

**TEITL: CYFLWYNO SHINGRIX® AR GYFER UNIGOLION AG IMIWNEDD GWAN (O FIS MEDI 2021)**

**Dyddiad dod i ben / adolygu:** Amherthnasol

**I'w weithredu gan:**

Meddygon Teulu  
Arweinwyr Imiwneiddio, Byrddau Iechyd  
Cyfarwyddwyr Iechyd y Cyhoedd,  
Byrddau Iechyd  
Cyfarwyddwyr Iechyd Sylfaenol, Iechyd  
Cymunedol ac Iechyd Meddwl, Byrddau  
Iechyd  
Dirprwy Gyfarwyddwr Gwasanaethau  
Iechyd y Cyhoedd, Iechyd Cyhoeddus  
Cymru  
Pennaeth y Rhaglen Brechu yn erbyn  
Clefydau Ataliadwy, Iechyd Cyhoeddus  
Cymru

Prif Weithredwr, Iechyd Cyhoeddus  
Cymru

**Er gwybodaeth i:**

Brif Weithredwyr, Byrddau Iechyd Lleol  
Cyfarwyddwyr Meddygol, Byrddau  
Iechyd  
Cyfarwyddwyr Gweithredol Nyrsio,  
Byrddau Iechyd

**Anfonir gan:**

Dr Frank Atherton, y Prif Swyddog Meddygol / Cyfarwyddwr Meddygol GIG Cymru

**Cyswilt yn Adran Iechyd a Gwasanaethau Cymdeithasol Llywodraeth Cymru**

Is-adran Iechyd y Cyhoedd, Llywodraeth Cymru, Parc Cathays, Caerdydd, CF10 3NQ

E-bost: [health.protection@gov.wales](mailto:health.protection@gov.wales)

**Dogfen amgaeedig:** Atodiad A

Annwyl gydweithiwr,

**Y Rhaglen Brechu Rhag yr Eryr**

1. O 01 Medi 2021, dylai practisau cyffredinol gynnig y brechlyn rhag yr eryr Shingrix®, nad yw'n fyw, i bawb sy'n gymwys i gael brechiad eryr ond sydd wedi'u gwrtharwyddo'n glinigol rhag derbyn y brechlyn byw Zostavax® oherwydd eu statws imiwneidd gwan.
2. Yn unol â gofynion presennol y rhaglen brechu rhag yr eryr, dylid cynnig y brechlyn i'r rhai sy'n dod yn gymwys yn 70 oed ac i unigolion yn eu 70au sydd heb eu brechu ac nad ydynt eto wedi cyrraedd eu pen-blwydd yn 80.
3. Mae cyflwyno'r brechlyn anactifedig hwn rhag yr eryr yn dilyn yr argymhelliad a wnaed gan y Cyd-bwyllgor ar Imiwneiddio a Brechu (JCVI) yn ei gyfarfod ym mis Chwefror 2018. Argymhellodd y pwyllgor y dylid cynnig Shingrix® i bob person sydd heb imiwneidd y mae Zostavax® yn cael ei wrtharwyddo ar ei gyfer ond sy'n gymwys i gael ei frechu o dan y rhaglen bresennol. Byddai hyn yn galluogi'r unigolion hyn i gael lefel debyg o ddiogelwch rhag yr eryr drwy frechu ag sydd gan y rhai nad oes ganddynt imiwneidd gwan ac sydd wedi cael eu brechu rhag yr eryr. Nododd y pwyllgor fod brechu yn y grŵp hwn yn arbennig o bwysig oherwydd yr achosion uwch o herpes zoster. Roedd y cyngor hwn yn gyson â'r argymhelliad gwreiddiol ar gyfer brechu pob oedolyn 70-79 oed gyda brechlyn zoster herpes. Erbyn hyn, mae digon o gyflenwad o frechlyn Shingrix® i allu gweithredu argymhelliad JCVI.
4. O ganol mis Awst, bydd Shingrix® ar gael i ymarferwyr cyffredinol ei archebu ar-lein drwy wefan ImmForm ar gyfer pobl sydd wedi'u gwrtharwyddo'n glinigol rhag Zostavax® oherwydd imiwneidd gwan.
5. Dylid defnyddio Shingrix® ar gyfer y rhai sy'n gymwys o 1 Medi 2021.
6. Mae Shingrix® yn gofyn am amserlen 2 ddos, gyda'r ail ddos yn cael ei roi o 2 fis (hyd at 6 mis) ar ôl y dos cyntaf.
7. Er mwyn cael digon o gyflenwad i'r rhai sydd angen ei gael, mae'n bwysig bod Shingrix® yn cael ei roi i'r rhai sy'n cael eu gwrtharwyddo'n glinigol rhag Zostavax® oherwydd eu statws imiwneidd gwan.
8. Dylai Ymarferwyr Cyffredinol barhau i gynnig Zostavax® i gleifion cymwys rhwng 70 a 79 oed nad oes ganddynt imiwneidd gwan.

9. Nid yw unigolyn sy'n cyrraedd ei ben-blwydd yn 80 oed yn gymwys bellach i gael brechiad rhag yr eryr fel mater o drefn, oherwydd bod y brechlyn yn lleihau o ran ei effeitholrwydd wrth i bobl fynd yn hŷn. Mae hyn yn adlewyrchu argymhelliad a wnaed gan JCVI yn 2010. Fodd bynnag, pan fo unigolyn yn troi'n 80 oed yn dilyn ei ddos cyntaf, dylid darparu ail ddos i gwblhau'r amserlen dau ddos ar gyfer Shingrix®
10. Mae'r eryr yn un o achosion pwysig afiachedd ymhlith pobl hŷn. 33.1% o bobl 70 oed a gafodd eu brechu yn 2020/21. Mae angen ymdrechion parhaus i nodi a brechu pob unigolyn cymwys er mwyn sicrhau gostyngiad parhaus yn nifer yr achosion o'r cyflwr gwanychol a phoenus hwn a'r cymhlethdodau sy'n gysylltiedig ag ef. Rwy'n annog cydweithwyr i fanteisio ar bob cyfle i gynnig brechiad rhag yr eryr i gleifion cymwys drwy gydol y flwyddyn i helpu i amddiffyn cymaint o bobl hŷn â phosibl rhag y salwch hwn sy'n gallu bod yn ddifrifol.

Rwy'n ddiolchgar am eich cefnogaeth barhaus i'r rhaglen imiwneiddio rhag yr eryr.

Yn gywir,



**Dr Frank Atherton**  
**Y Prif Swyddog Meddygol / Cyfarwyddwr Meddygol GIG Cymru**

## Atodiad A

1. This guidance is based on advice from the Joint Committee on Vaccination and Immunisation (JCVI), the UK's independent advisory committee of immunisation experts. Full detailed guidance will be available in the updated [chapter 28a](#) on Shingles (herpes zoster) included in 'the Green Book' (Immunisation against infectious disease). The chapter is in the process of being updated following a review by an Expert Working Group. The update will be published before September 2021.

### Incidence of shingles and vaccine uptake

2. Prior to the introduction of the vaccination programme, annual incidence of shingles for those aged 70 to 79 years was estimated to be around 790 to 880 cases per 100,000 people in England and Wales, with around 4% of cases in those aged 70 years and over resulting in complications including long term pain (post-herpetic neuralgia). Evaluation following the first five years of the vaccination programme in England showed vaccine effectiveness of 50% to 60% against GP consultations for herpes zoster. Vaccine effectiveness against consultations for post-herpetic neuralgia was estimated to be 66% (54% to 78%) and 75% (63% to 86%) in catch-up and routine cohorts respectively.
3. For the 2020/21 Shingles Immunisation Programme<sup>1</sup>, overall, 33.1% of those that turned 70 and 54.6% of those that turned 79 during the year (from 1 April 2020 to 31 March 2021) were vaccinated as at 28 March 2021. Compared to 2019/20 vaccine coverage decreased by 6.6% for 70 year olds and increased by 0.4% for 79 year olds. Latest data on uptake can be found on the Public Health Wales web site at:

<https://phw.nhs.wales/topics/immunisation-and-vaccines/shingles-and-shingles-immunisation/>

### Eligibility from 1 September 2021

4. From 1 September 2021, the non-live shingles vaccine Shingrix® may be offered to individuals where, due to their immunocompromised status, Zostavax® vaccine is clinically contraindicated as follows:

## **Routine programme**

- to individuals on or after their 70<sup>th</sup> birthday who are eligible for the shingles vaccination;

## **Catch up programme**

- to unvaccinated individuals in their 70s who have not yet reached their 80<sup>th</sup> birthday.
5. There is no requirement for practices to operate active call and recall systems but it would be good practice to do so. Priority should be given to maximising uptake when the patient becomes eligible at 70 years of age.
  6. Shingrix® requires a 2 dose schedule, with the second dose administered from 2 months (up to 6 months) following the first dose.
  7. Shingrix® can be administered at any time of year and can also be given alongside other vaccines such as flu and pneumococcal polysaccharide vaccine (PPV). The current advice is that shingles vaccines should not be given at the same time as COVID-19 vaccines, which require an interval of 7 days.
  8. Any individual who reaches their 80<sup>th</sup> birthday is no longer eligible for a shingles vaccination. However, where an individual has turned 80 years of age following their first dose, a second dose should be provided to complete the two-dose schedule for Shingrix®. Following a temporary extension in Wales due to the COVID-19 pandemic, individuals who have turned 80 years of age during the pandemic and missed the opportunity to be vaccinated may still be offered shingles vaccine up to 31 March 2022.

## **Patient Group Directions**

9. A Shingrix® vaccine patient group direction (PGD) from PHE will be made available on the PHW PGD template page, for Health Boards to locally develop and authorise for use locally.
10. <http://nww.immunisation.wales.nhs.uk/current-pgd-templates>

## **Vaccine supply**

11. From mid-August 2021, Shingrix® will be available to order online via the [ImmForm website](#) for [individuals for whom Zostavax® is clinically contraindicated due to immunocompromise](#). See the [ImmForm helpsheet](#) for information on registering for an ImmForm account. Ordering controls will be in place to balance incoming supply with demand. Details of ordering controls will be made available on ImmForm and in Vaccine Update in due course. Please make sure that stocks of shingles vaccine are rotated in fridges so that wastage is minimised. It is recommended that practices hold no more than two weeks' worth of stock.

## Identifying eligible patients

12. General Practices should offer the non-live shingles vaccine Shingrix® to all those who are eligible for shingles vaccination but are clinically contraindicated to receive the live vaccine Zostavax® due to their immunocompromised status.
13. The section on contraindications for Zostavax® in the Shingles (herpes zoster) Green Book chapter (28a) is being updated following a review by an Expert Working Group and will be published before the vaccine is introduced in September:  
<https://www.gov.uk/government/publications/shingles-herpes-zoster-the-green-book-chapter-28a>
14. Where General Practices undertake a search of their clinical system for eligible patients, search criteria should be adjusted to ensure patients eligible for vaccination but for whom Zostavax® is contraindicated are included for vaccination with Shingrix® from September 2021 and are invited for their second dose in good time.

## Funding

15. Funding for the routine Zostavax® shingles programme has already been transferred to health boards' core allocations. An 'in year' funding allocation for the Shingrix® programme in 2021-22 will be made to health boards. Further details will be provided shortly in a separate letter.

## Service arrangements

16. Service arrangements have been agreed with GPC Wales. The Directions to Local Health Boards as to the Financial Entitlements Directions 2013 will be amended accordingly.
17. GMS contractors can claim an Item of Service fee of £20.06 on completion of the final course of the Shingrix® vaccine i.e. after the 2<sup>nd</sup> dose in respect of each registered patient who meets the eligibility criteria and who has received the Shingrix® vaccines during the financial year ending 31 March.
18. If a GMS contractor has only been able to administer a single dose, a GMS contractor may claim £10.03 for that dose provided that;
  - a) the contractor states the reason(s) for only administering a single dose when making a claim, and
  - b) the LHB is satisfied by the reason(s) given by the contractor before it makes a payment for a single dose.

## **Data collection**

### **SNOMED codes for administration of Shingrix® vaccine**

19. SNOMED codes and GP IT systems will be updated to allow the recording of the two doses of Shingrix® in electronic health records from September 2021. The recommended SNOMED codes for recording administration of Shingrix® vaccine doses in electronic patient records are as follows:

	<b>SNOMED Concept ID</b>	<b>SNOMED DescriptionID</b>
<b>Shingrix® vaccine 1<sup>st</sup> dose</b>	<b>1326101000000105</b>	<b>Administration of first dose of vaccine product containing only Human alphaherpesvirus 3 antigen for shingles (procedure)</b>
<b>Shingrix® vaccine 2<sup>nd</sup> dose</b>	<b>1326111000000107</b>	<b>Administration of second dose of vaccine product containing only Human alphaherpesvirus 3 antigen for shingles (procedure)</b>

### **Information for healthcare professionals and patients**

20. The Shingles (herpes zoster) Green Book chapter (28a) is being updated and will be published before the vaccine is introduced in September:  
<https://www.gov.uk/government/publications/shingles-herpes-zoster-the-green-book-chapter-28a>
21. Healthcare professional information and guidance for the shingles vaccination programme will be updated to include the offer of Shingrix® for eligible patients and is available at:  
<https://www.gov.uk/government/publications/shingles-vaccination-guidance-for-healthcare-professionals> and also at:  
<http://nww.immunisation.wales.nhs.uk/shingles-vaccination-programme> (NHS Wales intranet only)
22. A training slide set will also be made available at:  
<http://nww.immunisation.wales.nhs.uk/resources-for-trainers> (NHS intranet only). An eLearning module is available for the shingles vaccination programme which will be updated and made available on ESR and via Learning@Wales. Information on how to access the eLearning module on Learning@Wales is available here:  
<https://phw.nhs.wales/topics/immunisation-and-vaccines/immunisation-elearning/>
23. Updated public information will be available online at:  
<https://phw.nhs.wales/topics/immunisation-and-vaccines/shingles-and-shingles-immunisation/> and resources will be available to order from:  
<https://phw.nhs.wales/services-and-teams/health-information-resources/>

## **Black Triangle Scheme**

24. Shingrix® is part of the Medicines and Healthcare products Regulatory Agency's (MHRA) [Black Triangle Scheme](#) for new medicines and vaccines to allow rapid identification of new safety information. Healthcare professionals are asked to report all suspected adverse reactions via the Yellow Card Scheme at: [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.

## **Vaccine coverage data collection**

25. Surveillance for shingles vaccination is carried out by Public Health Wales Vaccine Preventable Disease Programme, using the same methods as for other adult vaccination programmes. Read/ SNOMED coded data are collected from general practices using Audit+, based on nationally recommended codes. Routine surveillance reports are published through the Public Health Wales internet and intranet sites.

Links to surveillance reports:

Internet: <https://phw.nhs.wales/data/> (immunisation section)

Intranet (NHS only): <http://nww.immunisation.wales.nhs.uk/shingles-uptake>